Skip to main content
SpringerLink
Log in

Thymopentin and splenopentin as immunomodulators

Current status

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Splenopentin (SP-5, Arg-Lys-Glu-Val-Tyr) and thymopentin (TP-5, Arg-Lys-Asp-Val-Tyr) are synthetic immunomodulating peptides corresponding to the region 32–34 of a splenic product called splenin (SP) and the thymic hormone thymopoietin (TP), respectively. TP was originally isolated as a 5-kDa (49-amino acids) protein from bovine thymus while studying effects of the thymic extracts on neuromuscular transmission and was subsequently observed to affect T cell differentiation and function. TP I and II are two closely related polypeptides isolated from bovine thymus. A radioimmunoassay for TP revealed a crossreaction with a product found in spleen and lymph node. This product, named splenin, differs from TP only in position 34, aspartic acid for bovine TP and glutamic acid for bovine splenin and it was called TP III as well. Synthetic pentapeptides (TP-5) and (SP-5), reproduce the biological activities of TP and SP, respectively. It is now evident that various forms of TPs were created by proteolytic cleavage of larger proteins during isolation. cDNA clones have been isolated for three alternatively spliced mRNAs that encodes three distinct human T cell TPs. The immunomodulatory properties of TP, SP, TP-5, SP-5 and some of their synthetic analogs reported in the literature have been briefly reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meroni PL, Barcellini W, Frasca D, Sguotti C, Borghi M, De Bertolo G, Doria G, Zanussi C: In vivo immunopotentiating activity of thymopentin in aging humans: Increase of IL-2 production. Clin Immunol Immonupathol 1987; 42:151–159.

    CAS  Google Scholar 

  2. Barcellini W, Meroni PL, Borghi MO, Frasca D, Perego R, Doria G, Zanussi C: In vivo immunopotentiating receptor expression. Clin Immun Immunopathol 1988; 48:140–149.

    CAS  Google Scholar 

  3. Caruso C, Modica MA, Candore G, Di Lorenzo G, Durante M, Di Giulio C: In vivo thymopentin modulation of mitogen-responsiveness T cell precursor frequency. Int J Immunother 1989;3:133–137.

    Google Scholar 

  4. Frasca D, Adorini L, Mancini C, Doria G: Reconstitution of T cell functions in aging by thymosin α 1. Immunopharmacology1986; 11: 155–163.

    PubMed  CAS  Google Scholar 

  5. Doria G, D’Agostaro G, Garavini M: Age dependent changes of B cell reactivity and T cell T cell interaction in the in vitro antibody response. Cell Immunol 1980;15: 195–206.

    Google Scholar 

  6. Goldstein G: Isolation of bovine thymin: a polypeptide hormone of the thymus. Nature 1974;247:11–14.

    PubMed  CAS  Google Scholar 

  7. Audhya T, Schlesinger DH, Goldstein G: Complete amino acid sequences of bovine thymopoietin I, II, III: closely homologous polypeptides. Biochemistry 1981 ;20: 6195–6200.

    PubMed  CAS  Google Scholar 

  8. Goldstein G, Hofmann WW: Electrophysiological changes similar to those of myasthenia gravis in rats with experimental autoimmune thymitis. J Neurol Neurosurg Psychiat 1968;31:453–459.

    PubMed  CAS  Google Scholar 

  9. Goldstein G, Hofmann WW: Endocrine function of the thymus affecting neuromuscular transmission. Clin Exp Immunol 1969; 4:181–189.

    PubMed  CAS  Google Scholar 

  10. Basch RS, Goldstein G: Induction of T cell differentiation in vitro by thymin, a purified polypeptide hormone of the thymus. Proc Natl AcadSciUSA 1974;71:1474–1478.

    CAS  Google Scholar 

  11. Scheid MP, Goldstein G, Bosyse EA: The generation and regulation of lymphocyte populations: Evidence from differentiative induction systems in vitro. J Exp Med 1978;147:1727–1743.

    PubMed  CAS  Google Scholar 

  12. Weksler ME, Innes JB, Goldstein G: Immunological studies of aging. IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin32-36 J Exp Med 1978;148:996–1006.

    PubMed  CAS  Google Scholar 

  13. Goldberg EH, Goldstein G, Boyse EA, Scheid MP: Effect of TP5 analogue of thymopoietin on the rejection of male skin by aged and thymectomized female mice. Immunogenetics 1981;13:201–204.

    PubMed  CAS  Google Scholar 

  14. Goldberg EH, Goldstein G, Harman DB, Boyse EA: Contrasting effects of thymopoietin and splenopentin on the capacity of female mice to reject syngeneic male skin. Transplantation 1984:38:52–55.

    PubMed  CAS  Google Scholar 

  15. Lau CY, Freestone JA, Goldstein G: Effect of thymopoietin pentapeptide (TP-5) on autoimmunity. I. TP5 suppression of induced erythrocyte autoantibodies in C3H mice. J Immunol 1980;125:1634–1638.

    PubMed  CAS  Google Scholar 

  16. Lau CY, Goldstein G: Functional effects of thymopoietin32-36(, (TP-5) on cytotoxic lymphocyte precursor units (CLP-U). Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation. J Immunol 1980;124:1861–1865.

    PubMed  CAS  Google Scholar 

  17. Lau CY, Wang EY, Goldstein G: Studies of thymopoietin pentapeptide (TP-5) on experimental tumors. I. TP-5 relieves immunosuppression in tumor-bearing mice. Cell Immunol 1982;66:217–232.

    PubMed  CAS  Google Scholar 

  18. Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J: A synthetic pentapeptide with biological activity characteristic of thymic hormone thymopoietin. Science 1979;204:1309–1310.

    PubMed  CAS  Google Scholar 

  19. Audhya T, Scheid MP, Goldstein G: Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proc Natl Acad Sci USA 1984;81: 2847–2849.

    PubMed  CAS  Google Scholar 

  20. Diezel W, Waschke SR, Eckert R, Forner K: Induction and augmentation of mitogen-induced immune interferon production in human lymphocytes by a synthetic pentapeptide. Biomed Biochem Acta 1984;43:K9-K12.

    CAS  Google Scholar 

  21. Diezel W, Eckert R, Forner K, Sonnichsen N: Effect of splenopentin (SP-5) on the antibody formation in immunosuppressed mice. Exp Clin Endocrinol 1986; 87:215–218.

    PubMed  CAS  Google Scholar 

  22. Diezel W, Grumer S, Weber H, Maciejewski J, Volk HD: Synergistic effects of splenopentin and recombinant human granulocytemacrophage colony stimulating factor on myelopoiesis. J Invest Dermotol 1989;93:547.

    Google Scholar 

  23. Gruner S, Deizel W, Strunk D, Zwirner A, Sonnichsen N, Anhalt GJ: Stimulation of recruitment of epidermal Langerhans cells by splenopentin. Arch Dermatol Res 1990;281:526–529.

    PubMed  CAS  Google Scholar 

  24. Schlesinger DH, Goldstein G: The amino acid sequence of thymopoietin II. Cell 1975;5:361–365.

    PubMed  CAS  Google Scholar 

  25. Schlesinger DH, Goldstein G, Scheid MP, Boyse EA: Chemical synthesis of a peptide fragment of thymopoietin II that induces selective T cell differentiation. Cell 1975;5:367–370.

    PubMed  CAS  Google Scholar 

  26. Goldstein G: Radioimmunoassay for thymopoietin. J Immunol 1976; 117:690–692.

    PubMed  CAS  Google Scholar 

  27. Viamontes GI, Audhya T, Goldstein G: Immunohistochemical localization of thymopoietin with an antiserum to its synthetic Cys-thymopoietin 28–39. Cell Immunol 1986;100:305–313.

    PubMed  Google Scholar 

  28. Audhya T, Goldstein G: Amino acid sequence of thymopoietin isolated from skin. Ann N Y Acad Sci 1988;548:233–240.

    PubMed  CAS  Google Scholar 

  29. Zevin-Sonkin D, Ilan E, Guthemann D, Riss J, Theodor L, Shoham J: Molecular cloning of the bovine thymopoietin gene and its expression on different calf tissues: Evidence for a predominant expression in thymocytes. Immunol Lett 1992;31:301–309.

    PubMed  CAS  Google Scholar 

  30. Harris CA, Andryuk PJ Cline SW, Chan HK, Natarajan, A., Siekierka, JJ, Goldstein, G: Three distinct human thymopoietins are derived from alternatively spliced mRNAs. Proc Natl Acad Sci USA 1994;91: 6283–6287.

    PubMed  CAS  Google Scholar 

  31. Harris CA, Andryuk, PJ, Cline SW, Mathew S, Siekierka JL, Goldstein G: Structure and Mapping of the human thymopoietin (TMPO) gene and relationship of human TMPO beta to rat laminassociatedpolypeptide2. Genomics 1995;28:198–205.

    PubMed  CAS  Google Scholar 

  32. Berger R, Theodor L, Shoham J, Gokkel E, Brok-Simoni F, Avraham KB, Copeland NG, Jenkins NA, Rechavi G, Simon AJ: The characterization and localization of the mouse thymopoietin/lamin-associated polypeptide 2 gene and its alternatively spliced products. Genome Res 1996;6:361–370.

    PubMed  CAS  Google Scholar 

  33. Berger R, Theodor L, BrokSimoni F, Ben-Bassat H, Trakhtenbrot J, Shoham S, Rechavi G: Demonstration of thymopoietin transcripts in different haematopoietic cell lines. Acta Haematol 1995;93:62–66.

    PubMed  CAS  Google Scholar 

  34. Hara H, Hayashi K, Ohta K, Itoh N, Ohta M: A new thymopoietin precursor gene from human thymus. Biochem Mol Biol Intl 1994;34: 927–933.

    CAS  Google Scholar 

  35. Toda T, Ishijima Y, Matshusita H, Yoshida M, Kimura, N: Detection of thymopoietin-responsive proteins in nude mouse spleen cells by two-dimensional polyacrylamide gel electrophoresis and image processing. Electrophoresis 1994; 15:984–987.

    PubMed  CAS  Google Scholar 

  36. Lewis VM, Twomey JJ, Bealmear P, Goldstein G, Boyse EA: Age, thymic involution and circulating thymic hormone activity. J Clin Endocr Metab 1978;47:145–150

    PubMed  CAS  Google Scholar 

  37. Lewis V, Twomey JJ, Goldstein G, O’Reilly R, Smithwick E, Pahwa R, Pahwa S, Good RA, Schulte-Wisserman H, Horowitz S, Hong R, Jones J, Sieber O, Kirkpatrick C, Polmar S, Bealmear P: Circulating thymic-hormone activity in congenital immunodeficiency. Lancet 1977;2:471–475.

    PubMed  CAS  Google Scholar 

  38. Kirkpatrick CH, Greenberg LE, Chapman SW, Goldstein G, Lewis VM, Twomey JJ: Plasma thymic hormone activity in patients with chronic mucocutaneous candidiasis. Clin Exp Immunol 1978; 34:311–317.

    PubMed  CAS  Google Scholar 

  39. Goldstein G: Thymitis and myasthenia gravis. Lancet 1966; 2:1164–1167.

    PubMed  CAS  Google Scholar 

  40. Goldstein G, Whittingham S: Experimental autoimmune thymitis. An animal model of human myasthenia gravis. Lancet 1966; 2:315–318.

    PubMed  CAS  Google Scholar 

  41. Goldstein G: Reply to bovine thymin. Nature 1974;249:863–864.

    Google Scholar 

  42. Brand A, Gilmour DG, Goldstein G: Lymphocyte-differentiating hormone of Bursa Fabricius. Science 1976; 193:319–321.

    PubMed  CAS  Google Scholar 

  43. Scheid MP, Goldstein G, Hammerling U, Boyse EA: Lymphocyte differentiation from precursor cells in vitro. Ann N Y Acad Sci 1975; 249:531–540.

    PubMed  CAS  Google Scholar 

  44. Goldstein G, Audhya TK: Thymopoietin and thymopentin: Experimental studies. Surv Immunol Res 1985;4(S)1:1–10.

    PubMed  CAS  Google Scholar 

  45. Sunshine GH, Basch RS, Coffey RG, Cohen KW, Goldstein G, Hadden JW: Thymopoietin enhances the allogeneicresponseandcyclic GMP levels of mouse peripheral, thymus derived lymphocytes. J Immunol 1978;120:1594–1599.

    PubMed  CAS  Google Scholar 

  46. Audhya T, Talle MA, Goldstein G: Thymopoietin radioreceptor assay utilizing lectin-purified glycoprotein from a biologically responsive T cell line. Archs Biochem Biophys 1984;234:167–177.

    CAS  Google Scholar 

  47. Smith DD, Conlon JM, Petzel J, Chen L, Murphy RF, Morley BJ: Solid phase peptide synthesis and biological activity of bovine thymopoietin II (TP-II) Int J. Pept Protein Res 1994;44:183–191.

    CAS  Google Scholar 

  48. Abiko T, Sekino H: Synthesis of [Phe(4F)3] thymopoietin II and examination of its immunological effect of the impaired blastogenic response of T lymphocytes of uremic patients. Bioorg Med Chem 1995; 3:1369–1375.

    PubMed  CAS  Google Scholar 

  49. Goldstein G, Schlesinger DH: Thymopoietin and myasthenia gravis: neostigmine-responsive neuromuscular block produced in mice by a synthetic peptide fragment of thymopoietin. Lancet 1975;2:256–259.

    PubMed  CAS  Google Scholar 

  50. Scheid MP, Goldstein G, Boyse EA: Differentiation of T cells in nude mice. Science 1975;190:1211–1213.

    Google Scholar 

  51. Ranges GE, Goldstein G, Boyse EA, Scheid MP: T cell development in normal and thymopentin treated nude mice. J Exp Med 1982;156:1057–1064.

    PubMed  CAS  Google Scholar 

  52. Vaughn JB Jr, Stephens RL, Lenkinski RE, Heavner GA, Goldstein G, Rama Krishna N: Nuclear magnetic resonance analysis of Gd3+-induced perturbation in thymopoietin32-36. A study of amide and aromatic proton resonances. Arch Biochem Biophys 1982;217:468–472.

    PubMed  CAS  Google Scholar 

  53. Tischio JP, Patrick JE, Weintraub HS, Chasin M, Goldstein G: Short in vivo half life of thymopoietin 32–36 pentapeptide in human plasma. Intl J Peptide Res 1979; 14:479–484.

    CAS  Google Scholar 

  54. Duchateau J, Delespesse G, Bolla K: Phase variation in the modulation of the human immune response. Immunol Today 1983; 4:213–214

    Google Scholar 

  55. Tourwe D, Deloen, JL, Hallenga K, Van Bisnt G: Conformational properties of the pentapeptide fragment (32–36) of the thymic hormone thymopoietin. Int J Peptide Protein Res 1984;23:84–93.

    CAS  Google Scholar 

  56. Heavner GA, Audhya T, Kroon D, Goldstein G: Structural requirement for the biological activity of thymopentin analogs. Arch Biochem Biophys 1985; 242: 248–255.

    PubMed  CAS  Google Scholar 

  57. Duchateau J, Bolla K: Immunomodulation with TP-5: In vitro studies. Med Oncol Tumor Pharmacother 1989;6:19–23.

    PubMed  CAS  Google Scholar 

  58. Wedner HJ, Parker CW: Lymphocyte activation. Prog Allergy 1976;20:195–300.

    PubMed  CAS  Google Scholar 

  59. Duchateau J, Servais G, Cooman R, Collet H, Bolla K: In vitro influence of thymopentin on proliferative responses and phytohaemagglutinin-induced IL 2 production in normal human lymphocyte cultures. Surv Immunol Res 1985;4 (S)1:1 16–124.

    Google Scholar 

  60. Hu C, Radelli L, Scorza R, Bonara P, Perego R, Fantuzzi G: In vivo enhancement of NK cell activity by thymopentin. Int J Immunopharmacol 1990; 12:193–197.

    PubMed  CAS  Google Scholar 

  61. Fiorilli M, Sirianni MC, Sorrentino R, Testi U, Aiuti F: In vitro enhancement of bone marrow natural killer cells after incubation with Thymopoietin32-36 (TP-5). Thymus 1983;5:375–382.

    PubMed  CAS  Google Scholar 

  62. Cillari E, Milano S, Dieli M, Arcoleo F, Perego R, Leoni F, Gromo G, Severn A, Liew, FY: Thymopentin reduces susceptibility of aged mice to cutaneous leishmaniasis by modulating CD4 T cell subsets. Immunology 1992; 76:362–366.

    PubMed  CAS  Google Scholar 

  63. Brauer R, Thoss K, Henzgen S, Waldmann G: Effects of immunomodulator diacetylsplenopentin on antigen induced arthritis in rabbits. Agents Action 1992; 35:96–103.

    CAS  Google Scholar 

  64. Brauer R, Egg AJ, Henzgen S, Kriegsmann J, Thoss K: The effect of immunomodulatory thymic and splenic peptides and cyclosporin-A on antigen induced arthritis in rats. Agents Action 1993;38:C95-C97.

    Google Scholar 

  65. Sundal E, Bertelletti D: Management of viral infections with thymopentin. Arzneimittelforschung 1994;44:866–871.

    PubMed  CAS  Google Scholar 

  66. Nicoletti F, Zaccone P, Magro G, Barcellini W, Cavallaro V, Belli G, Concuzza C, Di Marco R, Meroni PL: The effects of thymopentin on the development of SLE like syndrome in the MRL/lpr-lpr mouse. Scan J Immunol 1994; 40:549–556.

    CAS  Google Scholar 

  67. Mattei M, Bach S, Di-Cesare S, Fraziano M, Placido R, Poccia F, Sammarco I, Moras AM, Bardone MR, Colizzi V: CD4-8-T cells increase in MRL/lpr mice treated with thymic factors. Int J Immunopharmacol 1994; 16:651–658.

    PubMed  CAS  Google Scholar 

  68. Gallo F, Morale MC, Sambataro D, Farinella Z, Scapagnini U., Marchetti B: The immune system response during development and progression of carcinogen induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin. Breast Cancer Res Treat 1993;27:221–237.

    PubMed  CAS  Google Scholar 

  69. Taylor DD, Gercel-Taylor C, Fowler WC, Weese JL: Enhancement of antitumor effects of combined chemoimmunotherapy. J Immunother 1993; 13:91–97.

    CAS  Google Scholar 

  70. Ghanta VK, Hiramoto NS, Soong SJ, Hiramoto RN: Effect of thymic hormone treatment on several immune functions of nude mice. MechAgeingDev 1991;58:245–254.

    CAS  Google Scholar 

  71. Barbera N, Palmicci T, Chiarenza A, Bartoloni G, Cordaro S, Greco S, Scapagnini U, Bernardini R: Radioprotective effects of the association thymopentin-interleukin-lα in the C57BL/6 mouse. Pharmacol Toxicol 1993;72:256–261.

    PubMed  CAS  Google Scholar 

  72. Ravagnan G, Falchetti R, Lanzilli G, Di Francesco P, Gaziano R, Favalli C, Garaci E: Effect of synthetic thymic hormones on the cocaine-induced inhibition of primary immune response in mice. Int J Immunopharmacol 1993; 15: 879–885.

    PubMed  CAS  Google Scholar 

  73. Braga M, Di Franscesco A, Gianotti L, Vignalli A, Costantini E, Socci C, Fortis C, Paganelli G, Di Carlo V: Thymopentin increases the survival of mice after allogeneic blood transfusion, bacterial gavage, and burn injury. Eur J Surg 1994; 160:345–350.

    PubMed  CAS  Google Scholar 

  74. Mallmann P, Krebs D: The effect of adjuvant combined chemo/ immunotherapy on immunological parameters and clinical course in patients with breast carcinoma. Zentralbl Gynakol 1991 ;113:697–706.

    PubMed  CAS  Google Scholar 

  75. Di Lauro L, Del Medico P, Carpano S, Cancrini A, Gionfra T, Vici P, Roselli M, Lopez M: Sequential sub-cutaneous thymopentin, interferon α2a and interleukin-2 in metastatic renal cancer. Tumori 1995;81:42–44.

    PubMed  Google Scholar 

  76. Denaro A, Stivala F, Mazzarino MC: Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy, radiotherapy. Acta Otorhinolaryngol Ital 1994; 14:611–625.

    PubMed  CAS  Google Scholar 

  77. Maurizio T, Belli G, Santarelli M, Raffetto N, Margherita T: Valutazione del trattamento con timopentina associato alla radiotgerapia nei tumori della testa e del collo. Clin Ter 1995;146:457–467.

    Google Scholar 

  78. Sortini A, Di Marco L, Navarra G, Donini A, Fiorentini G, Santini M, Sartori A, Donini I: Treatment with immunomodulating drugs of patients with operated cancer. Minerva Chir 1994;49:1101–1105.

    PubMed  CAS  Google Scholar 

  79. Gebbia R, Valenza A, Testa G, Borsellino CN, Gebbia N: A prospective randomized trial of thymopentin versus granulocytecolony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res 1994;14:731–734.

    PubMed  CAS  Google Scholar 

  80. AiutiF, BusincoL, Rossi P, Quinti I: Response to thymopoietin pentapeptide in a patient with DiGeorge Syndrome. Lancet 1980;i:91.

    Google Scholar 

  81. Aiuti F, Fierily M, Quinti I, Seminara R, Businco L, Galli E, Rossi P, Goldstein G: Thymopoietin pentapeptide treatment of primary immunodeficiencies. Lancet 1983;i:551–554.

    Google Scholar 

  82. Joffe MI, Sochett E, Pettifor JM, Rabson AR: A case of DiGeorge syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function. J Clin Lab Immunol 1982;8:69–73.

    PubMed  CAS  Google Scholar 

  83. Fiorilli, M, Sirianni MC, Pandolfi F, Quinti I, Tosti U, Aiuti F, Goldstein G: Improvement of NK activity of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency. Clin Exp Immunol 1981 ;45:344–351.

    PubMed  CAS  Google Scholar 

  84. Duchateau J, Servais G, Vreyers R, Delespesse G, Bolla K: Modulation of immune response in aged humans through different administration modes of thymopentin. Surv Immun Res 1985;4 (S):94–101.

    Google Scholar 

  85. Domzig W, Stadler BM, Herberman RB: Interleukin 2 dependence of human natural killer (NK)cell activity. J Immunol 1983;130:1970–1973.

    PubMed  CAS  Google Scholar 

  86. Williams RC, Montano JD, Bankhurs AD: Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinamia after TP-5 treatment. J Lab Clin Med 1983;101:152–160.

    PubMed  Google Scholar 

  87. Hsieh KH, Shaio, MF, Liao, TN: Thymopentin treatment in severe atopic dermatitis—clinical and immunological evaluations. Arch Dis Child 1992;67:1095–1002.

    PubMed  CAS  Google Scholar 

  88. Strannegard IL, Kang K, Cooper KD, Hanifen JM: FcIgG receptorbearing lymphocytes and monoclonal antibody-defined subsets in atopic dermatitis: Effect of treatment with thymopoietin pentapeptide (TP-5). Intl Arch Allergy Appl Immunol 1982;69:238–244.

    CAS  Google Scholar 

  89. Kang K, Cooper KD, Hanifen JM: Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte sub-populations in atopic dermatitis. J Am Acad Dermatol 1983;8:372–377.

    PubMed  CAS  Google Scholar 

  90. Stiller MJ, Shupack JL, Kenny C, Jondreau L, Cohen DE, Soter NA: A double blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol1994;30:597–602.

    PubMed  CAS  Google Scholar 

  91. Cooper KD: New theraupeutic approaches in atopic dermatitis. Clin Rev Allergy 1993; 11:543–559.

    PubMed  CAS  Google Scholar 

  92. Cooper KD: Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994; 102:128–137.

    PubMed  CAS  Google Scholar 

  93. Di Perri T, Laghi-Pasini F, Auteri A: Immunokinetics of a single dose of thymopoietin pentapeptide. J. Immunopharmacol. 1980;2:567–572.

    PubMed  Google Scholar 

  94. Thrower PA, Doyle DV, Scott J, Huskisson EC: Thymopoietin in rheumatoid arthritis. Rheumatol Rehabl 1982;21:72–77.

    CAS  Google Scholar 

  95. Abiko T, Onodera I, Sekino H: Effects of thymopoietin II fragments on E-rosette forming cells of rheumatoid arthritis patients. Chem Pharm Bull 1981;29:2322–2329.

    PubMed  CAS  Google Scholar 

  96. Veys EM, Hermanns P, Goldstein G, Kung, P, Schiinder J, Van Wauwe J: Determination of T lymphocyte sub-population by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. J Immunopharmacol 1981;3:313–319.

    CAS  Google Scholar 

  97. Veys EM, Huskisson EC, Rosenthal M, Vischer TL, Mielants H, Thrower PA, Scott J, Ott H, Scheijgrond H, Symdens J: Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis. Anna Rheum Dis 1982;41: 441–443.

    CAS  Google Scholar 

  98. Afeltra A, Galeazzi M, Basso P, Pietrucci A, De-Pita O, Ferri GM, Porzio F, Bonomo L: Immune imbalance in synovial fluid of rheumatoid arthritis patients: effects of intra-articular injection of thymopentin. J Biol Reg Homeost Agents 1991;5:71–75.

    CAS  Google Scholar 

  99. Ambrogi F, Ricciardi L, Nutini P, Vanacore P: CD5+ B lymphocytes and T cell subsets in a case of juvenile rheumatoid arthritis. Ann NY Acad Sci 1992;651:564–569.

    PubMed  CAS  Google Scholar 

  100. Danese C, Zavattaro E, Calisi L, Marciano F, Perego MA: Long term thymopentin treatment in systemic scleroderma. Curr Med Res Opin 1994;13:195–201.

    PubMed  CAS  Google Scholar 

  101. Borromei A, Draghetti M, Guerra L, Lozito A, Vargiu B: Multiple Sclerosis. Presentation of a case treated with thymopentin. Minerva Med 1995;86:227–232.

    PubMed  CAS  Google Scholar 

  102. Fattovich G, Giustina G, Alberti A, Guido M, Pontisso P, Favarato S, Benvegnu L, Ruol A: A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. J Hepat 1994:21:361–366.

    CAS  Google Scholar 

  103. Tovo PA, De Martino M, Rossi P, Cavagni, G, Masi M, Bardare M: The use of thymopentin in the prevention of recurrent infections of the respiratory system. Multicentre study. Minerva Pediatr 1993;45:505–510.

    PubMed  CAS  Google Scholar 

  104. Sundal E: Thymopentin prophylactic treatment in patients with recurrent respiratory infections. Br J Clin Pract 1993;47:198–204.

    PubMed  CAS  Google Scholar 

  105. Conant MA, Calabrese LH, Thompson SE, Poiesz BJ, Rasheed S, Hirsch RL, Meyerson LA, Kremer AB, Wang CC, Goldstein G: Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of double blind placebo controlled study. AIDS 1992;6:1335–1339.

    PubMed  CAS  Google Scholar 

  106. Goldstein G, Conant MA, Beall G, Grossman HA, Galpin JE, Blick G, Calabrese LH, Hirsh RL, Fisher A, Stampone P, Meyerson LA: Safety and efficacy of thymopentin in zidovudine (AZT) treated asymptomatic HIV infected subjects with 200–500 CD4 cells/mm3: a double blind placebo controlled trial. J AIDS Hum Retrovirol 1995;8:279–288.

    CAS  Google Scholar 

  107. Coppola S, Buccoliero G, Laddago V, Monno L, Perrone A, Guida G, Schiraldi O, Angarano G: Topical thymopentin therapy in HIV positive patients with recurrent oral candidiasis: A pilot study. Microbiologica 1996:19:351–356.

    PubMed  CAS  Google Scholar 

  108. Grismondi GL, Marini A: Thymopentin and cervico vaginal HPV infections associated with cervical intraepithelial neoplasia (CIN). Minerva Ginecol 1995;47:255–257.

    PubMed  CAS  Google Scholar 

  109. Markewitz A, Faist E, Lang S, Endres S, Fuchs D, Reichart B: Successful restoration of cell mediated immune response after cardiopulmonary by pass by immunomodulation. Thorac Cardiovasc Surg 1993; 105:15–24.

    CAS  Google Scholar 

  110. Vecchio R, Ferrara M, Mosca F, Messina G, Ignoto A, Di Martino M, Latteri F: Thymopentin in the prevention of post-splenectomy infections. Giorri Chir 1995;16: 253–255.

    CAS  Google Scholar 

  111. Launo C, De Grandi R, Augeri C, Palermo S, Cammardella MP, Mauro E, Doveri A, Maio M, Mantelli C: Changes in immune status due to anaesthesia and surgical interventions. The role of thymopentin and interleukin. Minerva Anesthesiol 1994;60: 427–435.

    CAS  Google Scholar 

  112. Thivolet J, Faure M, Nicolas JF, Maudiut G, Claudy A: Therapeutic use of TP-5 (thymopoietin 32–36) in sarcoidosis of the skin. Clin Immunol Immunopathol 1983; 26:350–360.

    PubMed  CAS  Google Scholar 

  113. Botturi M, Panzarasa R, Agostara B, Armarolli L, Belli M Barone D, Boccone F, Busutti L, Catalano E, Ciambellotti E: Effects of immunomodulation on antineoplastic radiotherapy. A controlled clinical study. Radiol Med 1993;86: 327–335.

    CAS  Google Scholar 

  114. Bisselli R, Fagiolo U, Nisini R, Paganelli R, D’offizi G, Ferrara R, Bertollo L, D’ Amelio R: Humoral response to influenza hemagglutinin: Oligoclonal spectrotype and failure of thymopentin as immunoadjuvant. Gerontology 1995:41:3–10.

    Google Scholar 

  115. Venditti A, Scimo MT, Poeta GD, Buccisano F, Stasi R, Mastino A, Grelli S, Favalli C, Garaci E, Papa G: Recombinant interferon-(2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes. A pilot study. Leukemia Lymphoma 1995; 16: 335–342.

    PubMed  CAS  Google Scholar 

  116. Vazhnychaya EM, Tarasenko LM, Deviatkina TO: Effect of thymopentin on non-specific resistance in chronic stress. Fiziol Zh 1994;40:96–99.

    Google Scholar 

  117. Chu AC, Patterson JAK, Goldstein G, Berger CL, Takezaki S, Edelson RL: Thymopoietin-like substance in human skin. J Invest Derm. 1983;81:194–197.

    PubMed  CAS  Google Scholar 

  118. Oliinyk BV, Sydorenko OV, Bohdanovych LV: Natural factor of splenin and mechanisms of its action. Fiziol Zh 1994:40:20–26.

    PubMed  CAS  Google Scholar 

  119. Oliinyk BV, Bogdanovych LV, Zhuravskyi MH: Role of nonprotein factor of splenin in the regulation of antibody formation. Fiziol Zh 1994:40:100–105.

    PubMed  CAS  Google Scholar 

  120. Kikot VA, Dziubko NI: Nonspecific active stimulation of the immune system in the combined treatment of rectal cancer. Vrach Delo 1989;7:46–48.

    PubMed  Google Scholar 

  121. Frolov VM, Peresadin NA, Dekaliuk IV, Pshenichnyi II: The tocopherol acetate and splenin correction of the immunological disorders in patients with viral hepatitis B. Lik Sprava 1992;4:90–91.

    PubMed  Google Scholar 

  122. Frolov VM, Peresadin NA, Vysotskii I, Tischenko AN, Pinskii LL: The immunomodulatory effect of vilozen and splenin in the treatment of patients with acute and chronic toxic allergic hepatitis. Lik Sprava 1993;5-6:70–72.

    PubMed  Google Scholar 

  123. Frolov VM, Peresadin NA, Ershova IB, Demenkov VR, Miankina AV: The immunomodulating action of vilozen and splenin in angina patients against a background of chronic bronchitis. Lik Sprava 1992;8:79–81.

    PubMed  Google Scholar 

  124. Frolov VM, Peresadin NA, Pustovoi I: Combined chemotherapy of toxic hepatitis in patients with pulmonary tuberculosis. Probl Tuberk 1992;5-6:30–31.

    PubMed  Google Scholar 

  125. Bereza NM, Selezneva SI, Mosalova NM, Boiko TI, Cherniakova VI, Shevtsova ZI, Kudriavtseva V: Enterobsorption in the treatment of ulcerative colitis patients. Lik Sprava 1992; 1:97–100.

    PubMed  Google Scholar 

  126. Epishin AV, Khabarova NA, Grytsiv VY, Venger YP: Idiopathic hypothyroidism. Combined treatment with immnomodifying drugs. Terapevt Arkh 1993;65: 39–42.

    CAS  Google Scholar 

  127. Isakova OL, Sepetov NF, Forner K, Erlich A: Enzymatic hydrolysis of splenopentin and its analogs in human serum. Bioorg Khim 1989; 15:453–459.

    PubMed  CAS  Google Scholar 

  128. Rastogi A, Singh VK, Biswas S, Haq W, Mathur KB, Agarwal SS: Augmentation of human natural killer cells by splenopentin analogs. FEBS Lett 1993;17:93–95.

    Google Scholar 

  129. Legarrec Y, Morin A, Chedid L: Modifications of natural killer activity in the mouse by MDP and various muramyl peptides relationship with adjuvant or infectious properties. Int J Immmunopharmacol 1985;7:343.

    Google Scholar 

  130. Kay N, Allen J, Morley JE: Endorphins stimulate normal human peripheral blood lymphocyte natural killer activity. Life Sci 1984;35:53–59.

    PubMed  CAS  Google Scholar 

  131. Bajpai K, Singh VK, Agarwal SS, Dhawan VC, Naqvi T, Haq W, Mathur KB: Immunomodulatory activity of met-enkephalin and its two potent analogs. Int. J. Immunopharmacol. 1995; 17:207–212.

    PubMed  CAS  Google Scholar 

  132. Sharma SD, Tsac V, Krahenbuhl JL, Lemington JS: Augmentation of mouse natural killer cellactivity by muramyldipeptide and its analogs. Cell Immunol 1981; 62:101–109.

    PubMed  CAS  Google Scholar 

  133. Chatterjee-Kishore M, Agrawal S, Singh VK, Mathur KB, Agarwal SS: Up regulation of HLA class-I gene transcription in K562 cells by analogs of splenopentin (SP-5). Biochem Mol Biol Intl 1997; 41:521–528.

    CAS  Google Scholar 

  134. Biswas S, Singh VK, Rastogi A, Sharan R, Hag W, Mathur KB, Agarwal SS: Stimulation of IL-2 production and CD2R expression by splenopentin analogs. Int J Immunopharmacol, in press.

  135. Weber HA, Maciejewski J, Eckert R, Schutt M, Deizel W, Volk, HD: Splenopentin (DAc SP-5) accelerates the restoration of myelopoietic and immune systems after sublethal radiation in mice. Int J Immunopharmacol 1990;12:761–768.

    PubMed  CAS  Google Scholar 

  136. Eckert R, Diezel W, Forner K, Pfuller V, Sonnichsen N, Von Baehr R: Histamine receptor bearing lymphocytes (HRL). VIII. Splenopentin accelerated reconstitution of the immunoresponsive after elimination of HRL. Allerg Immun 1986;37:267–272.

    Google Scholar 

  137. Diezel W, Eckert R, Muller GM, Forner K, Sonnichsen N: Splenopentin influence on antibody formation in immunosuppressed animals andonphagocyticcapability of human granulocytes. Arch Geschwultforsch 1989;59:161–164.

    CAS  Google Scholar 

  138. Eckert R, Diezel W, Schmidt R, Forner K, Volk HD: Splenopentin (DAc SP-5) accelerated reconstitution of antibody formation after syngeneic bone marrow transplantation. Exp Clin Endocrinol 1989;94:219–222.

    PubMed  CAS  Google Scholar 

  139. Evseev VA, Davydova TV, Fomina VG, Odariuk I, Repke H, Oeme P, Forner K: Splenopentin Modulator of immune and behavioral reactions in secondary immunodeficiency state induced by experimental alcoholism. Biull Eskp Biol Med 1991;111:637–639.

    CAS  Google Scholar 

  140. Liebermann HT, Thalmann G, Bartels T, Nockler A: Experiments on early protection against foot and mouth disease virus. Acta Virol 1993;37:181–183.

    PubMed  CAS  Google Scholar 

  141. Eckert R, Schmidt R, Volk HD, Diezel W, Sonnichsen N, von Baehr R: Splenopentin induced reconstitution of the immune response after total body irradiation: optimization of treatment regime. Exp Clin Endocrinol 1989;94:223–225.

    PubMed  CAS  Google Scholar 

  142. Eckert R, Volk HD, Deizel W, Maciejewski J, Heipe F, Forner K, von Baehr R: Prevention of graft-vs-host reaction induced immunodeficiency by treatment with splenopentin (DAc-SP-5). Allerg Immunol 1989;35;279–285.

    CAS  Google Scholar 

  143. Eckert R, Maciejewski J, Weber H, Volk HD, Deizel W, Forner K, von Baehr R: Splenopentin (DAcSP-5) influence on engraftment and graft vs host reaction after non-H2 bone marrow transplantation in mice. Exp Clin Endocrinol 1990;96:307–313.

    PubMed  CAS  Google Scholar 

  144. Simon HU, Forner K, Buttner A, Haroske D Vogt KH: The lymphocyte transformation test using mononuclear cells of elderly patients as a suitable in vitro method for the estimation of structure effect relationships of splenin peptides. Pharmazie 1990; 45:917–919.

    PubMed  CAS  Google Scholar 

  145. Simon HU, Reipert B, Haroske D, Forner K, Storz H: Age-dependent sensitivity of human lymphocytes to the immunomodulating effect of bovine and human diacetyl splenopentin. Allerg Immunol 1990;36:351–358.

    CAS  Google Scholar 

  146. Diezel W, Weber HA, Maciejewski J, Volk HD: The effect of splenopentin (DAc SP-5) on in vitro myelopoiesis and on AZTinduced bone marrow toxicity. Int J Immunopharmacol 1993;15: 269–273.

    PubMed  CAS  Google Scholar 

  147. Greiner J, Mihe M, Weber H, Stoimenov A, Sonnichsen N, Diezel W: Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica. Dermatol Monatsschr 1990;176:157–162.

    PubMed  CAS  Google Scholar 

  148. Martynov VF, Leont’eva LI, Sorochinskaia El: Effect of synthetic fragments of thymic peptide hormones on learning and memory processes. Fiziol Zh 1988;74:634–639.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Immunology, Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, 226 014, Lucknow, India

    Vijay K. Singh, Sumita Biswas & Shyam S. Agarwal

  2. Division of Biopolymers, Central Drug Research Institute, Lucknow, India

    Krishna B. Mathur & Wahajul Haq

  3. Department of Microbiology, RML Awadh University, Faizabad, India

    Satyendra K. Garg

Authors
  1. Vijay K. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumita Biswas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krishna B. Mathur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wahajul Haq
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satyendra K. Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shyam S. Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vijay K. Singh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, V.K., Biswas, S., Mathur, K.B. et al. Thymopentin and splenopentin as immunomodulators. Immunol Res 17, 345–368 (1998). https://doi.org/10.1007/BF02786456

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02786456

Key Words

Search

Navigation